E. Ohman J or Asset Management AB Invests $1.49 Million in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

E. Ohman J or Asset Management AB purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 5,400 shares of the biopharmaceutical company’s stock, valued at approximately $1,485,000.

A number of other hedge funds have also modified their holdings of the business. Ashton Thomas Private Wealth LLC acquired a new position in Alnylam Pharmaceuticals during the 2nd quarter worth about $26,000. Allspring Global Investments Holdings LLC lifted its stake in Alnylam Pharmaceuticals by 572.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 143 shares in the last quarter. Friedenthal Financial acquired a new position in Alnylam Pharmaceuticals during the 3rd quarter worth about $51,000. Altitude Crest Partners Inc. acquired a new position in Alnylam Pharmaceuticals during the 1st quarter worth about $30,000. Finally, Meeder Asset Management Inc. lifted its stake in Alnylam Pharmaceuticals by 1,237.5% during the 2nd quarter. Meeder Asset Management Inc. now owns 321 shares of the biopharmaceutical company’s stock worth $78,000 after acquiring an additional 297 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Down 3.0 %

NASDAQ:ALNY opened at $284.86 on Friday. The stock’s 50 day moving average price is $274.43 and its 200 day moving average price is $221.45. The company has a market capitalization of $36.03 billion, a PE ratio of -106.29 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.61. The company had revenue of $659.83 million during the quarter, compared to analysts’ expectations of $447.22 million. During the same quarter last year, the business posted ($2.21) earnings per share. The company’s revenue for the quarter was up 107.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on ALNY shares. Royal Bank of Canada reissued an “outperform” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Thursday, October 10th. The Goldman Sachs Group raised Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price target for the company from $198.00 to $370.00 in a research report on Friday, August 16th. Chardan Capital reaffirmed a “buy” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, October 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Thursday, October 10th. Finally, Barclays increased their price target on Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Six analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $290.86.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 20,250 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total value of $5,305,500.00. Following the transaction, the director now directly owns 136 shares in the company, valued at approximately $35,632. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 20,250 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total value of $5,305,500.00. Following the transaction, the director now directly owns 136 shares in the company, valued at approximately $35,632. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Yvonne Greenstreet sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the transaction, the chief executive officer now owns 73,441 shares in the company, valued at $20,563,480. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 50,398 shares of company stock worth $13,595,460. 1.50% of the stock is currently owned by insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.